Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.

NCT04846686 | Completed

• 1 other identifier: IRBN622021/CHUSTE
• Study Type: observational
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors. A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.

Conditions

Preeclampsia

Keywords

Preeclampsia; EG-VEGF; Prokineticin; cesarean; placenta pathological examination; pregnancy; PROK1 receptor; PROKR2 receptor

Outcome Measures

Primary Outcomes (2)

• Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry

  Measured by placenta pathological examination (immunohistochemistry technical).

  At delivery

• Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry

  Measured by placenta pathological examination (immunohistochemistry technical).

  At delivery

Secondary Outcomes (7)

• Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry

  At delivery

• Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry

  At delivery

• Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry

  At delivery

• Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical).

  At delivery

• Presence of at least one chronic maternal pathologies describe below

  At delivery

Study Arms (2)

preeclampsia group

25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized. Placenta pathological examination will be performed.

Biological: Placenta pathological examination

control group

10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized. Placenta pathological examination will be performed.

Biological: Placenta pathological examination

Interventions

Placenta pathological examination BIOLOGICAL

a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.

control group; preeclampsia group

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.

You may qualify if:

• All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.
• For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia
• For the control group: patient who had a normal pregnancy

You may not qualify if:

• Patient who gave birth naturally
• Underage patients or under guardianship
• Patients who do not speak or read French
• Childbirth under X

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Saint Etienne: lead
• Commissariat A L'energie Atomique: collaborator

Study Sites (1)

Chu Saint-Etienne

Saint-Etienne, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

placental

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Officials

• Tiphaine BARJAT, MD

  CHU SAINT-ETIENNE

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 13, 2021
• First Posted: April 15, 2021
• Study Start: June 1, 2022
• Primary Completion: December 31, 2022
• Study Completion: January 1, 2023
• Last Updated: July 3, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)